Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis.

Aya F, Gaba L, Victoria I, Fernandez-Martinez A, Ruiz-Esquide V, Pineda E, Tosca M, Viladot M, Pereira V, Malvehy J, Prat A, Arance A.

ESMO Open. 2016 Feb 8;1(1):e000032. eCollection 2016.

2.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
3.

Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis.

Benson Z, Gordon S, Nicolato P, Poklepovic A.

Case Rep Oncol Med. 2017;2017:8095601. doi: 10.1155/2017/8095601. Epub 2017 Dec 28.

4.

Ipilimumab in patients with melanoma and autoimmune disease.

Kyi C, Carvajal RD, Wolchok JD, Postow MA.

J Immunother Cancer. 2014 Oct 14;2(1):35. doi: 10.1186/s40425-014-0035-z. eCollection 2014.

5.

Ipilimumab-Induced Enteritis without Colitis: A New Challenge.

Messmer M, Upreti S, Tarabishy Y, Mazumder N, Chowdhury R, Yarchoan M, Holdhoff M.

Case Rep Oncol. 2016 Nov 8;9(3):705-713. eCollection 2016 Sep-Dec.

6.

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

Bostwick AD, Salama AK, Hanks BA.

J Immunother Cancer. 2015 May 19;3:19. doi: 10.1186/s40425-015-0064-2. eCollection 2015.

7.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

8.

Ipilimumab-induced acute severe colitis treated by infliximab.

Pagès C, Gornet JM, Monsel G, Allez M, Bertheau P, Bagot M, Lebbé C, Viguier M.

Melanoma Res. 2013 Jun;23(3):227-30. doi: 10.1097/CMR.0b013e32835fb524.

PMID:
23458760
9.

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.

Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ.

Cancer Biol Ther. 2015;16(5):662-70. doi: 10.1080/15384047.2015.1026507.

10.

Ipilimumab-induced toxicities and the gastroenterologist.

Cheng R, Cooper A, Kench J, Watson G, Bye W, McNeil C, Shackel N.

J Gastroenterol Hepatol. 2015 Apr;30(4):657-66. doi: 10.1111/jgh.12888. Review.

PMID:
25641691
11.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

12.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.

Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pföhler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG).

Cancer Immunol Immunother. 2018 May;67(5):825-834. doi: 10.1007/s00262-018-2134-z. Epub 2018 Feb 27.

PMID:
29487980
13.

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Minor DR, Chin K, Kashani-Sabet M.

Cancer Biother Radiopharm. 2009 Jun;24(3):321-5. doi: 10.1089/cbr.2008.0607.

PMID:
19538054
14.

Endocrine side effects induced by immune checkpoint inhibitors.

Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F.

J Clin Endocrinol Metab. 2013 Apr;98(4):1361-75. doi: 10.1210/jc.2012-4075. Epub 2013 Mar 7. Review.

PMID:
23471977
15.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
16.

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Camacho LH.

Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.

17.

Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report.

Akel R, Anouti B, Tfayli A.

Case Rep Oncol. 2017 May 23;10(2):456-461. doi: 10.1159/000475709. eCollection 2017 May-Aug.

18.

Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation.

Shah R, Witt D, Asif T, Mir FF.

Cureus. 2017 Apr 20;9(4):e1182. doi: 10.7759/cureus.1182.

19.
20.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

Supplemental Content

Support Center